{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:26:02Z","timestamp":1773833162112,"version":"3.50.1"},"reference-count":78,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2016,12,8]],"date-time":"2016-12-08T00:00:00Z","timestamp":1481155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Fibroblast growth factor-23 (FGF23) is a circulating member of the FGF family produced mainly by the osteocytes and osteoblasts that can act as a hormone. The main action of FGF23 is to lower phosphatemia via the reduction of urinary phosphate reabsorption and the decrease of 1,25(OH)2-D generation in the kidney. In the course of chronic kidney disease (CKD), plasma FGF23 concentration rises early, most probably to compensate the inability of the deteriorating kidneys to excrete an adequate amount of phosphate. However, this comes at the cost of FGF23-related target organ toxicity. Results of clinical studies suggest that elevated plasma FGF23 concentration is independently associated with the increased risk of CKD progression, occurrence of cardio-vascular complications, and mortality in different stages of CKD. FGF23 also contributes to cardiomyocyte hypertrophy, vascular calcification, and endothelial dysfunction. The impact of FGF23 on heart muscle is not dependent on Klotho, but rather on the PLC\u03b3\u2013calcineurin\u2013NFAT (nuclear factor of activated T-cells) pathway. Among the factors increasing plasma FGF23 concentration, active vitamin D analogues play a significant role. Additionally, inflammation and iron deficiency can contribute to the increase of plasma FGF23. Among the factors decreasing plasma FGF23, dietary phosphate restriction, some intestinal phosphate binders, cinacalcet (and other calcimimetics), and nicotinamide can be enumerated. Anti-FGF23 antibodies have also recently been developed to inhibit the action of FGF23 in target organs. Still, the best way to normalize plasma FGF23 in maintenance hemodialysis patients is restoring kidney function by successful kidney transplantation.<\/jats:p>","DOI":"10.3390\/toxins8120369","type":"journal-article","created":{"date-parts":[[2016,12,8]],"date-time":"2016-12-08T10:39:01Z","timestamp":1481193541000},"page":"369","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Fibroblast Growth Factor-23\u2014A Potential Uremic Toxin"],"prefix":"10.3390","volume":"8","author":[{"given":"Piotr","family":"Kuczera","sequence":"first","affiliation":[{"name":"Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice 40-027, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Adamczak","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice 40-027, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Wiecek","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice 40-027, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2016,12,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/jbmr.5650040407","article-title":"Parabiosis suggests a humoral factor is involved in X-linked hypophosphatemia in mice","volume":"4","author":"Meyer","year":"1989","journal-title":"J. Bone Miner. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1046\/j.1523-1755.2001.00064.x","article-title":"Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23","volume":"60","author":"White","year":"2001","journal-title":"Kidney Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.101545198","article-title":"Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia","volume":"98","author":"Shimada","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1053\/j.jrn.2013.01.024","article-title":"Fibroblast growth factor 23, Klotho and disordered mineral metabolism in chronic kidney disease: Unraveling the intricate tapestry of events and implications for therapy","volume":"23","year":"2013","journal-title":"J. Ren. Nutr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1210\/en.2008-0877","article-title":"Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression","volume":"150","author":"Ichikawa","year":"2009","journal-title":"Endocrinology"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Wang, X., Wang, S., Li, C., Gao, T., Liu, Y., Rangiani, A., Sun, Y., Hao, J., George, A., and Lu, Y. (2012). Inactivation of a novel FGF23 regulator, FAM20C, leads to hypophosphatemic rickets in mice. PLoS Genet., 8.","DOI":"10.1371\/journal.pgen.1002708"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"E1146","DOI":"10.1073\/pnas.1110905108","article-title":"Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice","volume":"108","author":"Farrow","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1159\/000443452","article-title":"C-Terminal to intact fibroblast growth factor 23 ratio in relation to estimated glomerular filtration rate in elderly population","volume":"41","author":"Owczarek","year":"2016","journal-title":"Kidney Blood Press. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.bbrc.2003.12.102","article-title":"FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa","volume":"314","author":"Shimada","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1210\/en.2003-1768","article-title":"Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis","volume":"145","author":"Larsson","year":"2004","journal-title":"Endocrinology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1247\/csf.29.91","article-title":"Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice","volume":"29","author":"Li","year":"2004","journal-title":"Cell Struct. Funct."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1681\/ASN.2008070783","article-title":"Initial FGF23-mediated signaling occurs in the distal convoluted tubule","volume":"20","author":"Farrow","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.bone.2012.05.015","article-title":"FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1\/2-SGK1 signaling pathway","volume":"51","author":"Andrukhova","year":"2012","journal-title":"Bone"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11154-011-9199-8","article-title":"The role of vitamin D in the FGF23, klotho, and phosphate bone-kidney endocrine axis","volume":"13","author":"Haussler","year":"2012","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Chanakul, A., Zhang, M.Y., Louw, A., Armbrecht, H.J., Miller, W.L., Portale, A.A., and Perwad, F. (2013). FGF-23 regulates CYP27B1 transcription in the kidney and in extra-renal tissues. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0072816"},{"key":"ref_16","first-page":"229","article-title":"FGF23 promotes renal calcium reabsorption through the TRPV5 channel","volume":"33","author":"Andrukhova","year":"2014","journal-title":"EMBO J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/emmm.201303716","article-title":"FGF23 regulates renal sodium handling and blood pressure","volume":"6","author":"Andrukhova","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"ref_18","first-page":"4003","article-title":"The parathyroid is a target organ for FGF23 in rats","volume":"117","author":"Galitzer","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ki.2015.290","article-title":"Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production","volume":"89","author":"David","year":"2016","journal-title":"Kidney Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/eurheartj\/ehq436","article-title":"Cardioprotective effect of calcineurin inhibition in an animal model of renal disease","volume":"32","author":"Reuter","year":"2011","journal-title":"Eur. Heart J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/ki.2014.215","article-title":"Parathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription","volume":"86","author":"Meir","year":"2014","journal-title":"Kidney Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"Isakova","year":"2011","journal-title":"Kidney Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.2009121293","article-title":"Forging forward with 10 burning questions on FGF23 in kidney disease","volume":"21","author":"Wolf","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrendo.2009.196","article-title":"The FGF23-Klotho axis: Endocrine regulation of phosphate homeostasis","volume":"5","author":"Razzaque","year":"2009","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1210\/jc.2009-1603","article-title":"Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active","volume":"95","author":"Shimada","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1681\/ASN.2006080936","article-title":"Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study","volume":"18","author":"Fliser","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Mannstadt","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease","volume":"305","author":"Isakova","year":"2011","journal-title":"JAMA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1093\/ndt\/gfq309","article-title":"FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment","volume":"25","author":"Seiler","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1093\/ndt\/gfp191","article-title":"High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients","volume":"24","author":"Jean","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1681\/ASN.2010121224","article-title":"FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis","volume":"22","author":"Kendrick","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"640","DOI":"10.7326\/0003-4819-152-10-201005180-00004","article-title":"The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: The Heart and Soul Study","volume":"152","author":"Parker","year":"2010","journal-title":"Ann. Intern. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2014.08.037","article-title":"Fibroblast growth factor 23 (FGF23) and mortality: The Ludwigshafen Risk and Cardiovascular Health Study","volume":"237","author":"Brandenburg","year":"2014","journal-title":"Atherosclerosis"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease","volume":"119","author":"Januzzi","year":"2009","journal-title":"Circulation"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.atherosclerosis.2009.05.013","article-title":"Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population","volume":"207","author":"Mirza","year":"2009","journal-title":"Atherosclerosis"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.2215\/CJN.02560310","article-title":"Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease","volume":"5","author":"Kanbay","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1093\/ndt\/gfp205","article-title":"Relationship between circulating FGF23 and total body atherosclerosis in the community","volume":"24","author":"Mirza","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.atherosclerosis.2009.01.001","article-title":"Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community","volume":"205","author":"Mirza","year":"2009","journal-title":"Atherosclerosis"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.cmet.2015.09.002","article-title":"Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy","volume":"22","author":"Grabner","year":"2015","journal-title":"Cell Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"E863","DOI":"10.1152\/ajpendo.00596.2012","article-title":"FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy","volume":"304","author":"Touchberry","year":"2013","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1172\/JCI83470","article-title":"FGF23 signaling impairs neutrophil recruitment and host defense during CKD","volume":"126","author":"Rossaint","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1210\/jc.2004-1039","article-title":"Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men","volume":"90","author":"Ferrari","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2215\/CJN.05040610","article-title":"Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease","volume":"6","author":"Moe","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2215\/CJN.07640711","article-title":"Acute effects of very-low-protein diet on FGF23 levels: A randomized study","volume":"7","author":"Torraca","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/ndt\/gfs405","article-title":"Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): Results of a randomized trial","volume":"28","author":"Sigrist","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2215\/CJN.05420709","article-title":"Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy?","volume":"5","author":"Oliveira","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2215\/CJN.09250912","article-title":"Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD","volume":"8","author":"Isakova","year":"2013","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1681\/ASN.2015020117","article-title":"Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD","volume":"26","author":"Isakova","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1161\/01.RES.87.7.e10","article-title":"Phosphate regulation of vascular smooth muscle cell calcification","volume":"87","author":"Jono","year":"2000","journal-title":"Circ. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1681\/ASN.2011101006","article-title":"Calcium deficiency reduces circulating levels of FGF23","volume":"23","author":"Lopez","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1681\/ASN.2009050559","article-title":"Intestinal npt2b plays a major role in phosphate absorption and homeostasis","volume":"20","author":"Sabbagh","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04211007","article-title":"A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients","volume":"3","author":"Cheng","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1523-1755.2004.00482.x","article-title":"Nicotinamide suppresses hyperphosphatemia in hemodialysis patients","volume":"65","author":"Takahashi","year":"2004","journal-title":"Kidney Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1159\/000362424","article-title":"Effect of niacin on FGF23 concentration in chronic kidney disease","volume":"39","author":"Rao","year":"2014","journal-title":"Am. J. Nephrol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1210\/jc.2012-2790","article-title":"Effect of a 300 000-IU loading dose of ergocalciferol (vitamin D2) on circulating 1,25(OH)2-vitamin D and fibroblast growth factor-23 (FGF-23) in vitamin D insufficiency","volume":"98","author":"Turner","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"624","DOI":"10.2215\/CJN.10030911","article-title":"Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23","volume":"7","author":"Leder","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1530\/EJE-10-0591","article-title":"Effects of vitamin D replacement therapy on serum FGF23 concentrations in vitamin D-deficient women in short term","volume":"163","author":"Uzum","year":"2010","journal-title":"Eur. J. Endocrinol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1074\/jbc.M408903200","article-title":"Circulating FGF-23 is regulated by 1\u03b1,25-dihydroxyvitamin D3 and phosphorus in vivo","volume":"280","author":"Saito","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1359\/JBMR.050718","article-title":"Fibroblast growth factor-23 is regulated by 1\u03b1,25-dihydroxyvitamin D","volume":"20","author":"Collins","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/ki.2010.352","article-title":"Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism","volume":"79","author":"Pereira","year":"2011","journal-title":"Kidney Int."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1093\/ndt\/gfr668","article-title":"Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol","volume":"27","author":"Hansen","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1161\/CIRCULATIONAHA.111.053405","article-title":"Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23","volume":"125","author":"Lim","year":"2012","journal-title":"Circulation"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2215\/CJN.03630509","article-title":"Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD","volume":"5","author":"Wetmore","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/ndt\/gfr384","article-title":"Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism","volume":"27","author":"Koizumi","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/cen.12326","article-title":"Cinacalcet treatment decreases plasma fibroblast growth factor 23 concentration in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism","volume":"80","author":"Kuczera","year":"2014","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ndt\/gft417","article-title":"Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects","volume":"29","author":"Martin","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1172\/JCI61405","article-title":"FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality","volume":"122","author":"Shalhoub","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1359\/jbmr.090509","article-title":"Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets\/osteomalacia","volume":"24","author":"Aono","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/jcph.570","article-title":"Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending dose trial treating adults with X-linked hypophosphatemia","volume":"56","author":"Zhang","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/jbmr.1923","article-title":"Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women","volume":"28","author":"Wolf","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Olauson, H., Lindberg, K., Amin, R., Sato, T., Jia, T., Goetz, R., Mohammadi, M., Andersson, G., Lanske, B., and Larsson, T.E. (2013). Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion. PLoS Genet., 9.","DOI":"10.1371\/journal.pgen.1003975"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1210\/jc.2008-2396","article-title":"FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: A prospective study","volume":"94","author":"Schouten","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.transproceed.2016.05.012","article-title":"Bone disease and serum fibroblast growth factor-23 levels in renal transplant recipients","volume":"48","author":"Coskun","year":"2016","journal-title":"Transplant Proc."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Economidou, D., Dovas, S., Papagianni, A., Pateinakis, P., and Memmos, D. (2009). FGF-23 levels before and after renal transplantation. J. Transplant.","DOI":"10.1155\/2009\/379082"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1432-2277.2006.00319.x","article-title":"Effects of tacrolimus, cyclosporin A and sirolimus on MG63 cells","volume":"19","author":"Krocker","year":"2006","journal-title":"Transpl. Int."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1530\/EJE-14-0457","article-title":"Soluble Klotho and intact fibroblast growth factor 23 in long-term kidney transplant patients","volume":"172","author":"Bleskestad","year":"2015","journal-title":"Eur. J. Endocrinol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/sj.ki.5001788","article-title":"Post-transplant hypophosphatemia: Tertiary \u2018Hyper-Phosphatoninism\u2019?","volume":"70","author":"Bhan","year":"2006","journal-title":"Kidney Int."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/8\/12\/369\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:28:13Z","timestamp":1760210893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/8\/12\/369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,8]]},"references-count":78,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,12]]}},"alternative-id":["toxins8120369"],"URL":"https:\/\/doi.org\/10.3390\/toxins8120369","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,8]]}}}